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ABSTRACT 
RENAL DYSFUNCTION WITH HEART FAILURE:  CARDIORENAL SYNDROME             
A Retrospective study at Charlotte Maxeke Johannesburg Academic Hospital 
INTRODUCTION  
The field of medicine has been challenged by the dual epidemic of heart failure and renal 
insufficiency. There is an increasing need to identify these patients at an early stage so as 
to delay progression to renal damage. Furthermore there is a lack of local data assessing 
the relationship between heart failure and renal dysfunction. 
AIMS  
• To identify the prevalence of renal dysfunction in patients attending the heart failure 
clinic at Charlotte Maxeke Johannesburg Academic hospital (Cardiorenal syndrome 
Type II) 
• To evaluate the relationship between severity of heart failure and severity of renal 
dysfunction 
• To compare heart failure with reduced ejection fraction (HFREF) variables between 
patients with and without renal dysfunction. 
METHODOLOGY  
This study is a single center retrospective study of patients attending Charlotte Maxeke 
Johannesburg Academic Hospital Heart Failure Clinic. Heart failure patients included in 
this study were those with an ejection fraction < 50% as this is an accepted definition for 
HFREF. Patients with HFREF were analyzed specifically for the following; presence of 
renal dysfunction, Ejection Fraction (EF), Systolic Blood Pressure (SBP), Diastolic Blood 
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Pressure (DBP), Haemoglobin (HB), New York Heart Association (NYHA) functional class, 
furosemide dose , six minute walk test (6MWT) and Minnesota Living with Heart Failure 
Questionnaire (MLFQ) score . 
Presence of renal dysfunction was identified based on the glomerular filtration rate (eGFR) 
value of less than 60ml/min/1.73m2 as this is the threshold eGFR below which 
complications of renal impairment appear. The eGFR was calculated using the 
Modification of Diet in Renal Disease (MDRD) abbreviated formula: 
(186.3 X serum creatinine) -1.154 x (age) -0.203 x (0.742 if female) x (1.212 if African)  
The control group consisted of patients attending the clinic who did not have renal 
dysfunction. 
RESULTS  
A total 242 files were reviewed. Forty-two files were excluded from the study due to lack of 
adequate study data recorded in the file. Data was collected and entered into a database, 
which was analyzed using the Statistics/Data Analysis Program (STATA) Version 10.0.  
The mean age of the study group was 53.3 years (SD± 15.05) with the youngest subject 
being 21 years old and the oldest subject aged 85 years. The mean SBP was 119mmHg 
and the mean DBP was 75mmHg.  
The mean eGFR was 72.01 ml/min/1.73m2. The overall prevalence of low eGFR 
(<60ml/min/1.73m2) in the sample population was 34.5 %. The prevalence in female and 
male patients with a low eGFR was 35% and 33.6% respectively. 
Analysis of MLFQ, 6MWT, DBP and age yielded a positive correlation with eGFR, which 
was statically significant (p<0.05). An insignificant correlation was obtained comparing 
eGFR with SBP (p=0.07), EF (p=0.69) and HB  (p=0.79). 
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The Analysis of Variance Test (ANOVA), showed a significant correlation between eGFR 
values across the different NYHA functional classes (p 0.012). Thus it was found that the 
higher the NYHA class (clinically worse) was associated with worse renal function. The 
mean eGFR for NYHA I was 77.05 ml/min/1.73m2, for NYHA II was 70.61 ml/min/1.73m2, 
for NYHA III was 64.13 ml/min/1.73m2 and NYHA IV was 50.02 ml/min/1.73m2. 
DISCUSSION  
The overall prevalence of low eGFR (<60ml/min/1.73m2) in this study was 34.5%, a finding 
consistent with international trials. The majority of patients in this study were in NYHA 
functional class I or II, thereby highlighting the fact that renal dysfunction is common in 
heart failure patients and starts early. 
Statistically significant values were also obtained between eGFR and 6MWT, MLFQ, 
furosemide dose, age and DBP. The patients with higher 6MWT have better effort 
tolerance, thereby classifying their heart failure as milder. This in effect confirms that 
higher eGFR patients have higher effort tolerance. Higher MLFQ scores and higher 
furosemide doses are inversely correlated to eGFR. The more subjective symptoms you 
have, and the higher doses of furosemide you need, is a reflection of the severity of the 
heart failure. With regards to age, there is a normal physiological decline in eGFR with 
increasing age.  
In this study a statistically significant negative correlation between eGFR and NYHA was 
found. Thus a higher NYHA class is associated with worse renal function. This suggests 
that the clinically more advanced the patient, the poorer the renal function. 
Also, the prevalence of low eGFR (<60ml/min/1.73m2) within each NYHA class, as 
expected, increased with increasing NYHA class. It was 27% for NYHA I, 38% for NYHA II, 
40% for III, while class IV had 80% of low eGFR prevalence 
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CONCLUSION  
The findings of this study confirm that the cardio-renal syndrome is common in a local 
cohort of heart failure patients. The study also suggests that renal dysfunction starts in the 
early stages of heart failure (NYHA I/II) and becomes more prevalent in patients with more 
advanced stages of heart failure. These findings highlight the need to treat heart failure 
patients early after presentation and more appropriately if we are to decrease 
complications such as renal dysfunction, thereby improving morbidity and mortality. 
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LIST OF ABBREVIATIONS 
 
μg/L : micrograms per liter 
g/dl  : grams per deciliter 
 
mg  : milligrams 
 
6MWT : Six minute walk test 
 
ACE  : Angiotensin Converting Enzyme 
 
ACE-I  : Angiotensin Converting Enzyme Inhibitor 
 
ADHF : Acute Decompensated Heart Failure 
 
ANOVA  : Analysis of Variance Test 
 
ARB  : Angiotensin Receptor Blocker 
 
CCF  : Congestive Heart Failure 
 
CKD   : Chronic Kidney Disease 
 
DBP  : Diastolic Blood Pressure  
EF             : Ejection Fraction 
eGFR        : Estimated Glomerular Filtration Rate  
HB  : Haemoglobin 
 
HF  : Heart Failure 
 
HFREF : Heart Failure with Reduced Ejection Fraction 
 
HFPEF : Heart Failure with Preserved Ejection Fraction 
 
MLFQ        : Minnesota living With Heart Failure Questionnaire  
MRA  : Mineralocorticoid Receptor Blocker 
N  : Total Number 
 
No.  : Number 
 
NYHA : New York Heart Association 
 
SBP           : Systolic Blood Pressure 
SNS           :  Sympathetic Nervous System  
SD  : Standard Deviation 
 
STATA : Statistics/ Data Analysis Program 
 
WHO  : World Health Organization 
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Chapter 1:  LITERATURE REVIEW  
 
1.1 Background  
Heart failure remains the main cause of hospitalization in patients aged more than 65 
years.1 Chronic Heart Failure (CHF) is a challenging condition to treat as the quality of life 
is severely affected. Despite great advances in the medical and device therapy of CHF 
secondary to left ventricular systolic dysfunction, life expectancy remains reduced with a 
significant impact on quality of life .The latter is a reflection not just of the poor exercise 
reserve but also of the co-morbidities that are associated with CHF such as renal 
dysfunction, anaemia, arrhythmias and sleep apnea. The coexistence of renal dysfunction 
and heart failure in the same patient is referred to as “ Cardio-renal Syndrome” and this 
has an extremely poor prognosis.2  
Definitions  
Cardio-renal syndrome (CRS) 
There is no single definition that describes CRS. The term CRS has generally been 
reserved for the decline of renal function in the setting of advanced heart failure. Several 
definitions have been proposed for worsening renal function and these include a 
26.5umol/l increase in serum creatinine from baseline, an increase in serum creatinine 
above a threshold of 221umol/l, a 25% increase in creatinine from baseline, or a 
combination of these factors.3, 4 
Ronco et al.5 recently provided a more detailed classification of chronic renal failure in 
cardiac patients as follows:  
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Type 1- Acute Heart Failure resulting in acute kidney injury 
Type 2- CHF causing progressive kidney disease  
Type 3- Abrupt primary worsening of kidney function causing acute cardiac dysfunction, 
which manifests as HF (Reno-cardiac Syndrome) 
Type 4 - Primary chronic kidney disease contributing to cardiac dysfunction 
Type 5 - Systemic disorders causing both cardiac and renal dysfunction  
 
Heart failure  
The main terminology used to describe heart failure is based on the left ventricular ejection 
fraction (EF). Heart failure is now classified into: 
{a} Heart failure with preserved EF (HFPEF)  
{b} Heart failure with reduced ejection fraction (HFREF) 
A normal EF is regarded as an EF above 50%. Severity of heart failure is graded using the 
New York Heart Association (NYHA) classification:  
•  NYHA I - no limitation to the physical activity. 
• NYHA II - some limitation to the physical activity. 
• NYHA III - marked limitation to physical activity.  
• NYHA IV – inability to carry out any physical activity without discomfort. 
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Renal dysfunction  
In 2002 the Kidney Disease Outcomes Quality Initiative (KDOQI) classification was 
published to stage kidney disease based on the kidney function using the glomerular 
filtration rate (eGFR), irrespective of the diagnosis. 
• Stage 1 - eGFR  > 90 ml/min/1.73m2 
• Stage 2  - eGFR   60 – 89 ml/min/1.73m2  
• Stage 3 - eGFR    30 – 59 ml/min/1.73m2 
• Stage 4 - eGFR   15 – 29 ml/min/1.73m2 
• Stage 5 - eGFR  < 15 ml/min/1.73m2  (End stage kidney disease)  
 
1.2 Prevalence of renal dysfunction in heart failure  
Data from various sources demonstrate that approximately 20%- 40% of patients admitted 
to hospital for acute decompensated heart failure (ADHF) have associated renal 
dysfunction and end stage kidney disease.6 Cowie et al7 enrolled 248 patients with ADHF 
across eight European countries. The six-month follow-up showed that about a third of 
patients developed worsening renal function during their hospitalization. 
Another study performed on 1004 patients admitted for a primary diagnosis of HF from 11 
different hospitals, showed that worsening renal function developed in 27% of patients 
which happened within the first three days.8 This large cohort study demonstrates that 
worsening renal failure occurs in HF patients and is in associated with adverse outcomes. 
In this study, association remained strong in old as well as young patients.  
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1.3 Renal Dysfunction and prognosis in heart failure  
Heart failure is a dynamic syndrome that inhibits the ability of the heart to function as a 
pump to support physiological circulation. Heart failure and kidney function are closely 
interrelated in health and in disease. Renal function is commonly quantified by serum 
creatinine levels, or more precisely by estimated glomerular filtration rate (eGFR). Normal 
renal function is defined as eGFR values greater than 90ml/min/1.73m2. 
Even mildly decreased kidney function has shown to increase the mortality in heart failure 
patients. Hillege et al, showed a constant risk relationship of a 7 % increase in mortality for 
every 10ml/min decrease in eGFR.9 Large heart failure international trials like SOLVD10,11 
have pointed out the degree of renal impairment in heart failure. These studies showed 
that renal dysfunction occurs early in CHF and will be discussed later. 
A retrospective analysis in South Africa by Inglis et al12, showed that out of the 163 black 
patients in the study group, only 12% had an eGFR < 60ml/min/1.73m2. The prevalence in 
this study was much lower as compared to that found in the SOLVD trials. This could be 
explained by the average age of the South African cohort being much younger (48 years) 
and the likelihood of concomitant atherosclerotic disease being lower, as compared to the 
SOLVD cohort. No other local data assessing renal function in heart failure have been 
published. 
Fonarow GC et al13 found that the death rates doubled (9.4%) in patients with a serum 
creatinine level of 265umol/l or more. The Acute Decompensating Heart Failure National 
Registry (ADHERE) database which reported data over 100 000 patients with heart failure 
requiring hospitalization, showed the best predictor of outcome included both blood-urea & 
creatinine14. In the Valsartan in Acute Myocardial Infarction Trial (VALIANT)15, which 
included patients post myocardial infarction receiving good medical therapy, those with 
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eGFR lower than median had 1.5 times chance of adverse events such as death or 
myocardial infarction. 
Despite the poor understanding of this complex disease entity, it is evident that coexistent 
renal dysfunction in the setting of heart failure worsens prognosis, irrespective of the 
degree of renal impairment. 
 
1.4 Factors contributing to renal dysfunction in heart failure. 
There are multiple risk factors for the increased incidence of CRS: older age, diabetes, 
uncontrolled HTN, anaemia, anti inflammatory drugs, diuretics, angiotensin converting 
enzyme inhibitors, prior myocardial infection, NYHA functional class, elevated cardiac 
troponins. 
Ø Reduced renal perfusion is largely thought to be related to decreased cardiac output. 
However this is not always clinically evident. In the CORONA study16, an international 
trial with over 5000 patients, 24% of the entrants had creatinine >130umol/l. The mean 
eGFR was < 60ml/min/1.73m2, indicating that majority of patients in CORONA would 
be classified as having at least Stage 3 chronic kidney disease. This is despite the fact 
that the mean arterial blood pressure was 129/76mmhg and 37% of the entrants were 
in NYHA FC I-II. This shows that depressed renal function does not appear to be 
characterized by a low output state as a significant number of these patients present 
with normal or elevated blood pressure. 
Ø Impaired left ventricular function leads to hemodynamic derangements like low stroke 
volume and cardiac output, arterial under filling, elevated atrial and venous pressures. 
These hemodynamic changes trigger a variety of compensatory neuro-hormonal 
adaptations including activation of the sympathetic nervous system and the renin-
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angiotensin-aldosterone system (RAAS) and increase in the release of vasopressin 
and endothelin-1, which promotes salt and water retention and systemic 
vasoconstriction. This adaptation contributes to the preservation of perfusion to the 
vital organs by maintenance of systemic pressure via arterial vasoconstriction in other 
circulations, including the renal circulation. However systemic constriction increases 
cardiac afterload, which reduces cardiac output, which further decreases renal 
perfusion. The most deleterious action of the RAAS in CRS is the activity of 
angiotensin II, which results in the formation of the reactive oxygen species.17 
Increased NADPH-oxidase activity, has been found in the hearts of patients with end 
stage HF. When the vicious cycle begins, it causes structural and functional irreparable 
damage to the heart and kidneys. 
Ø Increased renal venous pressure by virtue of increased abdominal pressure or 
increased central venous pressure will decrease eGFR.18 
Ø Venous congestion is shown to play a role in renal dysfunction in heart failure 
patients.19 
Ø Right Ventricular (RV) dilatation and dysfunction can adversely affect the kidneys 
through RV dilatation, impairing left ventricular (LV) filling and therefore forward output 
(Reverse Bernheim phenomenon). 20 
Ø B-type natriuretic peptide (BNP) effects provide some beneficial effects. It inhibits 
RAAS, endothelin-1 and other such vasoconstrictors. As the name suggests, it 
promotes diuresis, enhances sodium excretion and may even increase eGFR. 
Ø Renal dysfunction has been attributed to multiple factors coupled with pharmacological 
interventions that leads to renal sodium and water retention, which in turn leads to 
extracellular fluid expansion.21 
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Ø Excess SNS (sympathetic nervous stimulation) induces cardiac cell apoptosis, 
hypertrophy and focal myocardial necrosis.22 It contributes to RAAS activation by 
directly stimulating renin release. SNS also induces inflammation by noradrenaline 
mediated cytokine production from the liver and the heart.23, 24 Imbalance between the 
RAAS, SNS and inflammation provokes insult to the kidney. 
Ø During a condition of ischemia/ reperfusion damage to the kidneys, hydrogen peroxide 
formation by the mono amino oxidase enzymes, induce a pro-apoptotic cascade in the 
proximal tubular cells 25 thereby leading to renal dysfunction. 
Ø  Cardio-renal-anaemia syndrome: The interaction between chronic heart failure, 
chronic kidney insufficiency and anaemia which is termed as the cardio-renal-anaemia 
syndrome. This syndrome causes a worsening of cardiac and renal function. Reduced 
cardiac output and renal blood flow worsen renal function. Reduced erythropoietin 
(EPO) production and reduced erythropoiesis causes anaemia. Anaemia exacerbates 
heart failure by increasing the heart rate and stroke volume. 
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TREATMENT OF RENAL DYSFUNCTION IN HEART FAILURE 
 
Patients with co-existing CHF and chronic kidney disease are especially challenging to 
treat. As mentioned earlier, there are studies linking renal dysfunction and adverse clinical 
outcomes in HF patients. It is important to note that heart failure treatments also negatively 
impact the glomerular filtration rate during treatment, which can denote a worse 
prognosis.26 
 
On the other hand, some treatments of heart failure that are thought to decrease eGFR 
through intra-renal mechanisms reduce rates of mortality and morbidity.27 Due to the 
complex nature of treatment, earlier intervention, more frequent monitoring and timely 
referral are important. 
 
I will briefly review the general approaches currently available and some specific 
interventions currently proposed or under investigation, with a focus on the concept that 
heart failure is a progressive condition and that interventions should be guided by disease 
stage, patient clinical presentation and presence of co-morbidities. 
 
•  MAINTAINING EUVOLEMIA. In hypovolemia, GFR can be reduced by the reduction of 
effective plasma volume and renal hypoperfusion. In contrast, hypervolemic patients 
may have impaired renal function because of renal venous congestion, reduced renal 
perfusion pressure or renal compression. Therefore, intense and sudden variations in 
the plasma volume of patients with decompensated heart failure should be strongly 
avoided. 
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• SALT RESTRICTION. There is a paucity of data on the effect of restriction of salt intake 
in HF patients. Various guidelines advocate salt restriction based on the rationale that 
salt restriction improves BP control (a major risk factor in HF) and hence improve heart 
failure management. A registry in Sweden with over 60 000 patients, showed that a low 
sodium DASH diet reduces the long term rate of incident HF and thereby decreasing 
concomitant renal disease38.   
• ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE-i) and angiotensin receptor 
blockers (ARB) can decrease filtration pressure within the glomerulus by inducing 
systemic hypotension and predominant vasodilation of the glomerular efferent arteriole. 
This manifests as a decrease in eGFR. The safety and efficacy of accepting ‘modest’ 
changes in glomerular filtration rate have been shown previously, 54 by illustrating that an 
acute increase in creatinine of up to 30% that stabilized within the first 2 months of ACE-i 
therapy was noted to have preservation of renal function in the longer term. Testani et al, 
27 demonstrated that not only eGFR itself but also the factors that drive the change in 
eGFR predict clinical outcomes.  Within the SOLVD trial,11 early reduction in eGFR was 
associated with increased mortality within the placebo group as opposed to the group on 
enalapril. It is important to note that this trial excluded patients with creatine levels above 
177umol/L as there is no evidence for safety above these levels.  
•  
• BETA BLOCKERS: The influence of beta-blockers on renal function is much less 
understood. A small study suggested that initiation of beta-blocker therapy was 
associated with preserved renal function in heart failure patients with a lower baseline 
GFR but not in those with a higher baseline GFR, although these results are yet to be 
confirmed.28 
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•  STATINS: Data from studies in patients with chronic kidney disease suggest that statins 
may preserve renal function.29 In the Greek Atorvastatin and Coronary Heart Disease 
Evaluation (GREACE) study,30 the effect of atorvastatin administered at a dose 10 to 80 
mg/day on renal function was studied. At the end of the study, creatinine clearance had 
worsened by 12% in the atorvastatin group and 4.9% in the “usual care” group. 
Additionally, a meta-analysis of 13 prospective trials that evaluated the effect of statins 
on renal function showed that treatment with statins reduced the decline in GFR with a 
possible trend towards proteinuria reduction.31 Even though statins may have a positive 
influence on renal function of patients with heart failure, its effect on overall prognosis 
has not yet been thoroughly studied. 
 
• RENAL DENERVATION: Hyperactivation of the SNS is involved in the pathophysiology 
of hypertension, renal insufficiency and heart failure. Devices have been developed for 
ablation of the renal sympathetic nerves by radiofrequency-emitting catheter that are 
inserted percutaneously through the femoral artery and then advanced to the renal 
artery. Renal function as assessed by serum creatinine, eGFR and cystatin C 
concentrations were not remarkably changed from baseline. There are ongoing trials are 
investigating the safety and efficacy of renal denervation in patients with CHF, and its 
application as a preventive measure for renal dysfunction remains speculative.32 
 
• LOW DOSE DOPAMINE: IN ADHF, the infusion of low-dose dopamine has been shown 
to induce renal vasodilation and natriuresis mediated by “the stimulation of the dopamine 
alpha-1 and alpha-2 receptors in the proximal tubule, the thick ascending loop of Henle 
and the cortical collecting ducts”.33 In a meta-analysis of 61 trials that had patients at risk 
for acute renal failure to receive low-dose dopamine or placebo, dopamine was 
associated with a 24% increase in urine output, 4% relative decrease in serum creatinine 
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level and 6% relative increase in measured creatinine clearance.34 In patients with 
systolic heart failure, low-dose dopamine has also been demonstrated to increase renal 
blood flow and GFR. In a clinical trial of patients with acute decompensated heart failure, 
the combination of infused low-dose furosemide and low-dose dopamine was found to 
be as effective as a high-dose furosemide infusion in terms of the clinical and diuretic 
response. Furthermore this combination was associated with a significantly lower rate of 
worsening renal function, suggesting a reno-protective effect in this patient population.35 
 
 
•  DIURETICS: Concerns regarding diuretic use involve ototoxicity, hypocalcaemia and 
diuretic-induced hypovolemia. These conditions become particularly important in the 
setting of ADHF because of the presence of hypotension, right ventricular failure and 
elevated intra-abdominal pressure as well as use of high diuretic doses. Thus, a reno-
protective strategy could potentially be derived from the continuous infusion of smaller 
doses of a diuretic. However one recent clinical trial has shown that there is no 
significant difference in renal function when furosemide was given by bolus or by 
continuous infusion.53 
 
In conclusion, the role of beta-blockers, angiotensin converting enzyme inhibitors (ACE-i), 
angiotensin receptor blocker (ARB) and mineralocorticoid receptor antagonist (MRA) are 
well established in CHF. There is increasing body of evidence to show both renal and 
cardiac benefits of ACE-I and ARB therapy blocker in CKD.  However, a lot more focus 
needs be placed on clarifying the pathways through which agents influence renal function 
and the effects thereof on overall prognosis. 
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Chapter 2: STUDY DETAILS 
 
2.1 Aims and Objectives 
• To define the prevalence of co-morbid renal dysfunction in patients attending the heart 
failure clinic at Charlotte Maxeke Johannesburg Academic Hospital. 
•  To evaluate the relationship between the severity of heart failure and severity of renal 
dysfunction.  
•  To compare HFREF variables between patients with and without renal dysfunction.  
• To determine the etiology of heart failure in patients attending the heart failure clinic at 
Charlotte Maxeke Johannesburg Academic Hospital. 
 
2.2 Study Design and Methodology  
The study is a single center retrospective study of patients attending the Charlotte Maxeke 
Johannesburg Academic Hospital Heart Failure Clinic. The patient files were analyzed 
specifically for presence of renal dysfunction, ejection fraction, blood pressure, NYHA 
functional class, furosemide dose, six-minute walk test duration and The Minnesota Living 
with Heart Failure Questionnaire score.  
Heart failure patients included in the study are those with Ejection Fraction < 50% as this 
is the inclusion requirement for patients to be at followed up at the Heart failure Clinic at 
Charlotte Maxeke Academic Hospital. 
The presence of probable renal dysfunction in this study was defined as a threshold of 
<60ml/min/1.73m2, as this is the threshold below which complications of renal impairment 
appear18. 
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The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) 
abbreviated formula, which is: 
(186.3 x serum creatinine) -1.154 x (age)-0.203 x (0.742 if female) x (1.212 if African)  
The control group consisted of participants attending the clinic who did not have renal 
dysfunction.  
The two groups were compared using: 
• Six minute walk test 
• Participant’s symptom scores; using the Minnesota Living with Heart Failure 
Questionnaire (MLHFQ - Appendix I). 
• Ejection Fraction 
• Blood Pressure 
• eGFR 
• Dose of Furosemide 
• ACE inhibitor use 
• New York Heart Association (NYHA) functional class 
	  
2.2.1 Objective Assessment Measures 
A] The Minnesota Living with Heart Failure Questionnaire (MLHFQ)  
The MLFQ consists of 21 questions, which measure the effects of heart failure and its 
treatment on an individual’s quality of life. The MLHFQ incorporates key physical, 
emotional, social and psychological dimensions of quality of life. The answer for each 
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question is assigned a numerical score from 0 to 5. The total score may vary from 0 – 105, 
with lower scores reflecting fewer heart failure symptoms and improved quality of life. The 
questionnaire has been validated57 and is the questionnaire being used at the heart failure 
clinic at Charlotte Maxeke Johannesburg Academic Hospital. 
 
 B] The six-minute walk test 
The six-minute walk test was originally designed to test exercise tolerance in chronic 
respiratory or cardiac disease. Recently it has been used as a performance-based 
measure that assesses the functional exercise capacity. The six-minute walk test (6MWT) 
measures the maximum distance in meters that an individual is able to walk in six minutes, 
without supplementary oxygen, on a hard and flat surface. The test is simple to perform, 
requires inexpensive equipment, is safe and is fairly reproducible provided it is well 
standardized. The individual can walk at his or her own pace, resting intermittently if 
necessary for a total of six minutes. The 6MWT can be used to detect changes following 
therapeutic interventions and predict hospitalization and mortality. A lower score (reflecting 
less distance covered in 6 minutes) shows a worse functional assessment. The normal 
distance in healthy adults ranges from 400m to 700m. Walking less than 300 m during the 
6MWT is shown to be a prognostic marker of cardiac death in patients with mild-to-
moderate heart failure. 21 
C] Ejection fraction (EF)  
Ejection Fraction represents the volumetric fraction of the blood that is pumped out of the 
ventricle with each cardiac cycle. Imaging via echocardiography allows meaningful 
mathematical expression of defining EF. In a healthy 70kg individual the typical EF is 
between 50-65%. Damage to the myocardium from whatever cause will result in a fall in 
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the contractile function of the heart and thus there will be a concomitant fall in EF.  By 
definition HFREF the ejection fraction is less than 50%.  
 
 
D] Blood Pressure  
Blood Pressure is determined by the amount of blood pumped by the heart as well as 
taking into account the resistance to blood flow in the arteries. The more blood the heart 
pumps and the narrower the arteries, the higher the Blood Pressure.  
 E] Estimated GFR  
According to the National Kidney Foundation practice guidelines, glomerular filtration is the 
best measurement to assess renal function. eGFR is a marker of the amount of the 
glomerular filtrate formed each minute in the nephrons of both kidneys which is measured 
by the rate of clearance of creatinine. The presence of kidney disease will lower the eGFR. 
There are five stages of chronic kidney disease as stated earlier.  
F] Furosemide  
Furosemide is used in patients with congestive cardiac failure to enhance urinary sodium 
excretion, thereby maintaining euvolemia and improving heart failure symptoms. The 
dosage of Furosemide required to minimize symptoms can be used as an indicator of the 
severity of heart failure. 
 
G] ACE inhibitors 
ACEi block the conversion of angiotensin I to angiotensin II, thereby lowering arteriolar 
resistance. The effects of this can lead to lower resistance in blood vessels in the kidneys 
which leads to improved natriuresis. Further advantages include its ability to decrease 
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plasma norepinephrine levels, thus breaking the deleterious circle of sympathetic and 
renin angiotensin system activation, and thereby causing the downward spiral in cardiac 
function in congestive heart failure.  
 
H] The New York Heart Association (NYHA) classification 
NYHA classification grades the severity of heart failure symptoms into four functional 
classes; NYHA I being mild heart failure symptoms and NYHA IV being severe. It is widely 
used in clinical practice and research as it provides a standardization of the severity of HF 
and response to treatment. 
  
2.2.2 Inclusion Criteria 
Patients diagnosed with systolic heart failure, HFREF, (EF < 50%), attending the Heart 
Failure Clinic at Charlotte Maxeke Johannesburg Academic Hospital. 
2.2.3 Exclusion Criteria: 
• Incomplete or missing data recorded in files. 
• Co-morbid respiratory disease. 
2.2.4 Limitations of the study 
English is often not the first language of our patient group. Therefore the Minnesota Living 
with Heart Failure Questionnaire (MLHFQ) may not be accurately completed. 
Disadvantages of a retrospective analysis such as poor record keeping are unavoidable. 
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2.2.5 Strengths of this study include: 
A highly experienced heart failure study team, headed by two senior cardiologists, that has 
been consistent for many years reviewed all the patients. The blood results are obtained 
from the same laboratory (National Health Laboratory Service – NHLS). 
2.2.6 Statistical analysis 
Data was collected and entered into a database using Microsoft Office Excel 2011. The 
data was analyzed using the Statistics/Data Analysis Program (STATA) Version 10.0.  
A] Prevalence 
Prevalence was calculated using the number of renal dysfunction patients divided by the 
total number of patients included in the study – the ratio was multiplied by 100 and 
expressed as a percentage. 
 
B] MLFQ, 6MWT, Furosemide Dose, SBP, DBP, Haemoglobin with eGFR correlation 
The relationship between the variables listed above, were analyzed using the pairwise 
correlation statistical test. 
C] NYHA and eGFR 
The relationship between NYHA functional class and eGFR concentration was assessed 
using the Analysis of Variance test (ANOVA). 
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                            CHAPTER 3: RESULTS 
 
A total 242 files were reviewed from the Heart Failure Clinic at Charlotte Maxeke 
Johannesburg Academic Hospital.  Forty-two files were excluded from the study due to 
lack of study data recorded in the file. 
 
3.1 DEMOGRAPHICS  
3.1.1  Patient Demographics   
The study group comprised of 104 (52%) males and 96 (48%) females. The mean age of 
the study group was 53.1 years. The youngest subject was aged 21 years old and the 
oldest subject was aged 85 years old. The mean age for males was 57.09 and the mean 
age of females was 48.71. 
 
 
NUMBER  
total number of patients  200 
GENDER  
Males 104 
Females 96 
AGE  
Range  21 - 85 
Mean +/- SD  53.06 
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Median                                 55.5                                  
Male mean  +/- SD 57.08 
Female mean  +/- SD 48.70 
SD of age  15.13 
Table 1: Patient demographics 
 
3.1.2 eGFR 
The mean eGFR recorded was 72.01ml/min/1.73m2. The mean eGFR in male subjects 
was 72.30ml/min/1.73m2 and in female subjects was mean 71.70ml/min/1.73m2. The 
overall prevalence of low eGFR (< 60ml/min/1.73m2) in the sample population was 34.5%. 
The male prevalence for low eGFR was found to be 17.5%( 35 males) and in females 17% 
(34 females). 
 eGFR <60 
Female 34 
Male 35 
Total 69 
Percentage 34.5% 
Table 2: Sex prevalence of low eGFR 
 
 
3.1.3 New York Heart Association Class 
There were 85 patients with NYHA class I, 85 patients with class II, 25 patients with class III and 5 
patients with class IV.  
 
NYHA I 85  (42.5%) 
NYHA II 85 (42.5%) 
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NYHA III 25 (12.5%) 
NYHA IV 5 (2.5% 
Table 3: Patients Percentage in NYHA class 
Based on the 69 patients that had low eGFR (<60ml/min/1.73m2), 23 patients were in 
NYHA class I, 32patients were in NYHA class II, 10 patients were in class III and the 
remaining 4patients were in class IV. Majority of the patients in the study belonged to 
NYHA class I and II. The prevalence of low eGFR within each class is tabulated as follows: 
Prevalence of low eGFR ( <60%)   within each NYHA class 
NYHA  I 23 (27%) 
NYHA   II 32 (38%) 
NYHA    III 10 (40%) 
NYHA     IV  4 (80%) 
Table 4: Prevalance of low eGFR in different NYHA class 
 
3.1.4 Haemoglobin 
The mean Hb in the study population was 13.19g/dl .  The overall prevalence of anaemia 
in the sample population was 19.5 % (39 patients) with male and female prevalence of 
21.1%  and 17.7% respectively. 
 Number Percentage 
Anemic Males 22 21.1% 
Anemic Females 17 17.7% 
Total Anemic patients 39 19.5% 
Table 5: Prevelance of Anaemia  
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3.5 Analysis of Minnesota Score/ Six-minute walk test/ Ejection Fraction/ 
Systolic Blood Pressure/ Diastolic Blood Pressure / Furosemide dose  
 
The mean Minnesota Score was 35.62 (SD ±26.66) and the median was 28. Evaluation of 
the 6MWT found a mean of 383.25 meters (SD ± 98.3) and a median of 400 meters. The 
mean furosemide dose was 61.60mg (SD ± 48.74) and the median was 118. 
 
PARAMETER RESULTS 
Minnesota score   
Mean ±SD 35.62 ( SD ±26.66)  
Median  28 
6 Minute Walk Test (meters)   
Mean ±SD 383.25  ( SD ±  98.3) 
Median  400 
Ejection fraction  
Mean  27.76 
Median  26.50 
SBP  
Mean  119.12 
Median  118 
DBP  
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PARAMETER RESULTS 
Mean  75.91 
Median  75 
Furosemide  dose (mg)   
Mean ± SD  61.60 (SD ±  48.74) 
Median  118 
Table 6: Mean/Median valves of Minnesota score, six-minute walk test, Ejection fraction, 
Systolic Blood Pressure, Diastolic Blood Pressure, Furosemide dose.  
 
3.3 Pairwise correlation of variables with estimated GFR  
 
 n R value P value 
MLFQ 196 -0.179 0.012 
6MWT 183 0.222 0.003 
Furosemide 161 -0.218 0.006 
SBP 200 0.127 0.072 
DBP 200 0.156 0.027 
EF 200 0.028 0.698 
HB 200 -0.019 0.794 
AGE 200 -0.422 0.000 
Table 7: Pairwise correlation with regards to eGFR 
 
The study found that the MLFQ, 6MW, Furosemide, DBP and Age were significantly 
correlated to eGFR.  On the other hand SBP, EF and HB did not show any correlation to 
eGFR. The graphs for the individual correlations are shown below. 
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Figure 1: Correlation between eGFR and Minnesota Living with Heart Failure Questionnaire 
 
 
 
 
 
 
 
 
 
Figure 2: Correlation between eGFR and six-minute walk test 
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Figure 3: Correlation between eGFR and Furosemide dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Correlation between eGFR and Systolic Blood Pressure 
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Figure 5: Correlation between eGFR and Diastolic Blood Pressure 
 
 
 
 
 
 
 
 
 
 
Figure 6: Correlation between eGFR and Ejection Fraction 
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Figure 7: Correlation between eGFR and Haemoglobin 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Correlation between eGFR and Age 
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3.4 ANOVA Analysis of NYHA with eGFR (ml/min/1.73m2 )    
 
The Analysis of Variance Test (ANOVA) was conducted to assess if there was a difference 
in eGFR values by NYHA functional class. Of interest is that this study showed that 
the mean eGFR was significantly lower with higher NYHA class (p < 0.012).  
 Descriptives  
 eGFR  
NYHA NUMBER OF 
PATIENTS 
MEAN  STD.DEVIATION 
I 85 77.05 22.94 
II 85 70.61 24.06 
III 25 64.13 25.39 
IV 5 50.02 15.25 
TOTAL  200 72.02 24.09 
Table 8: ANOVA analysis with eGFR 
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CHAPTER 4: DISCUSSION  
 
4.1 Demographics 
The study was conducted on a sample of 200 patients (n=200). Of this, 48% were females 
and 52% were males. The mean age of the study patients was 53.3 years. The mean ages 
for males was 57.4 years and for females was 48.8 years. The mean age in this study is a 
decade younger than other published data. 8,9 
4.2   Prevalence of low eGFR 
The overall prevalence of low eGFR (<60mL/min/1.73m2) was 34.5%. There was not much 
difference between male and female prevalence (50.7% vs 49.3%).  
Large heart failure international trials including SOLVD Prevention (SOLVD-P) and SOLVD 
Treatment (SOLVD-T) have pointed out the degree of renal impairment in heart failure. 
Interestingly, 21% of the patients in the SOLVD-P trial had eGFR <60ml/min/1.73m2. This 
figure is all the more remarkable, as the patients in this trial were New York Heart 
Association (NYHA) functional class I-II (mild heart failure). In the SOLVD-T Trial, 35% of 
the patients had eGFR <60ml/min/1.732 and the majority of these patients were NYHA 
Class II. Our study shows similar suggestions, as 85% of our cohort was NYHA I/II. 
A local, South African study, conducted by Inglis et al12 in 2007 showed that only 12% (out 
of a study group of 163 black African patients) had an eGFR <60ml/min/1.73m2. This 
number is significantly lower than Western values and could be explained by the average 
age of their South African study cohort being younger (48 years). The mean age of the 
patient group included in this study was higher at 53.3 years and thus the likelihood of 
atherothrombotic disease being higher, thereby contributing to comparative prevalence’s 
to international studies. Also, their cohort involved fewer patients (163 black patients) who 
were newly diagnosed heart failure patients. Our study involved various races and most of 
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our patients had established heart failure that were chronic attendees to the heart failure 
clinic. 
4.3 eGFR and New York Heart Association Class 
One-way analysis of variance (ANOVA) was conducted to assess whether there was a 
difference in the eGFR by NYHA level. There is sufficient evidence to suggest that 
individuals with different NYHA levels have different eGFR scores. The mean eGFR 
decreases with increasing NYHA class. The p value was 0.012, which can conclude that 
individuals with different NYHA have different eGFR scores. The results indicate that 
patients in NYHA class I have eGFR scores that are significantly higher that NYHA II (p 
value=0.008), NYHA III (p value=0.002) and NYHA IV (p value=0.001). This means that 
there is an inverse relationship between eGFR and NHYA levels.  
 
The difference in average eGFR by NYHA levels is illustrated below. 
 
Figure 9: Correlation between eGFR and NYHA 
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found similar results. SBP was 119mmHg (Minimum 80mmHg and Maximum 200mgHg, 
and mean DBP was 76mmHg (minimum 50mmHg and maximum of 133mgHg). 
4.4 eGFR and Minnesota score: 
As expected, a significant positive correlation was found between eGFR and the 
Minnesota score (p value= 0.012). It must come with no surprise that patients with a higher 
severity of heart failure have a poorer physical, emotional, social and psychological health. 
Poor kidney functions only aggravate the quality of life further. This is all very stressful - 
and it becomes difficult to cope with the physical effects of kidney failure. 
4.5 eGFR and Six minute walk test 
Significant correlation was noted between eGFR and the six-minute walk test (p 
value=0.003). The six-minute walk test accurately assesses the patient’s effort tolerance. 
The results are a good indicator of the severity of heart failure based on the functional 
class. 
Patients with renal dysfunction, like CKD, are mostly inactive and have reduced physical 
functioning and performance36. 
 A recent study was done on a group of 83 patients with CKD37 .The study patients had to 
partake in 150 minutes of moderate intensity exercise (per week) together with education 
about behavior and lifestyle changes. There was an 11 percent increase in their maximal 
aerobic capacity of those in the study group, while those in the control group had a 1 
percent decline. Importantly, patients in the exercise group also showed improved heart 
function. However, larger studies with longer follow-ups are needed before we can be sure 
that this type of program is beneficial to renal dysfunction patients. 
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Resistance and aerobic exercise programs should be started at relatively low intensity 
thereby slowly increased as tolerated by symptoms so as to avoid injury and 
discontinuation of exercise.36 
The risk of both musculoskeletal and cardiac types of adverse events is higher with the 
high intensity exercise than with sub maximal exercise39. 
4.6 eGFR and Furosemide dose 
Patients with more severe heart disease require higher doses of furosemide and this 
explained the positive correlation between eGFR and furosemide (p value= 0.006).  
The ability of furosemide to act at very low levels of GFR55 encouraged its popularity in the 
therapy of renal edema and oliguria of chronic renal failure. Existing data also pointed that 
there was an increase in the renal circulation following furosemide56. It was also noted that 
furosemide shortens the evolution and reduces the number of dialysis hours. The 
recommended dose of furosemide is about 40 - 200 mg / day. However doses unto 4000 
mg have been used before with no major toxic effects being noted40. Intravenous 
administration takes effect in a few minutes and thereafter remains active for unto 6 to 8 
hours. It has also been found that there is no difference between administering IV bolus 
furosemide vs IV continuous infusion furosemide53.  
4.7 eGFR and Haemoglobin 
Anaemia is not so prevalent in earlier stages of chronic kidney disease. A study has 
shown that patients with stage III renal disease have a rate of concurrent anaemia of 
5.2%, as opposed to a worse rate of 44.1% in those with stage IV disease. (42)  
Silverberg et al43 described the "cardio-renal-anaemia syndrome," which refers to a vicious 
cycle where decreased kidney function leads to reduced erythropoietin production and, 
thence, anaemia. 
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The morbidity and mortality depend not only on the underlying etiology of the patient's 
anaemia but also the stage of the disease. The etiology of anaemia in advanced disease, 
tends to be multifactorial (eg. decreased red blood cell production due to lack of 
erythropoietin, increased red blood cell hemolysis [intravascular or extravascular], as well 
as more blood loss due to multiple veno-punctures for various investigations). 
It has been shown that black patient together with an increased prevalence of anaemia 
have also a four fold increased risk of developing chronic kidney disease compared to 
white patients44.   
The CHOIR (Correction of Haemoglobin and Outcomes in Renal Insufficiency) trial45, 
showed that a high haemoglobin target is associated with a increased risk of progression 
of CKD, which is apparently augmented by concurrent smoking.  
 
Severe anaemia leads to a regulatory compensatory left ventricular hypertrophy (LVH). 
Such LVH will lead to precipitation of CHF, which will cause a decline in renal perfusion 
and thereby resulting in further kidney damage. Levin et al46 estimated that for every 1g/dl 
decrease in HB concentration, there is a 6% risk of LVH in patients with chronic kidney 
disease. 
4.8 eGFR and Age 
There was a negative and significant correlation between the eGFR and age (p value= 
0.00) which is consistent with international studies .  Cross sectional studies have 
uniformly shown that the GFR declines steadily with age. It starts at age 30–40 years, with 
an increased rate of decline after age 65–70 years.48 
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In the original studies of Davies and Shock49 the estimated decline in GFR was 0.96 
ml/min/year or rather 10 ml/min/decade.  
The decline in GFR is a result of a progressive changes in the vascular tree; “ related to 
the effect of oxidative stress and telomere shortening, or perhaps linked to an action of 
angiotensin II”.50  
 
Among the 548 normal participants studied by Rowe et al51 the creatinine clearance rate 
fell from 140 ml/min/1.73m2 to about 97 ml/min/1.73m2 from age 30 years to age 80 years.  
 
In conclusion, GFR slowly declines with ageing as a normal “biological phenomenon linked 
to organ senescence”.  
 
4.9 eGFR and Diastolic Blood Pressure 
On comparison of eGFR with the diastolic blood pressure, a statistically significant 
correlation was obtained (p value= 0.027). The relationship between blood pressure and 
the kidneys is complex and each is seen to adversely affect the other.  There are other 
international studies that have yielded similar result. In the Renal Iohexol Clearance Study 
in Tromso 6 (RENIS T6)52, 1593 subjects ( aged 50-62 years)  were studied and analysis 
of the association between blood pressure and e GFR were made. Importantly, patients 
with Diabetes, Chronic kidney disease or Cardiovascular disease were excluded. This 
study demonstrated that an increase in the diastolic blood pressure had a slightly reduced 
eGFR in the middle aged healthy cohort.  
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THE FUTURE 
This study highlights the burden of renal dysfunction in heart failure patients. A prevalence 
of Cardio-Renal syndrome has been found to be as high as 34.5%. It points out the need 
for effective strategies in treating heart failure aggressively and thereby decrease the rate 
of renal dysfunction which holds a poorer prognosis. The limitations of this study are that it 
is a retrospective analysis and does not reflect any data on mortality/morbidity or 
prognosis. It also does not study the effect of specific therapy on cardiorenal syndrome.  
Potential future studies at the heart failure clinic include: 
- Study evaluating benefits pre and post specialist intervention. 
- The effect of adding ACE-i to eGFR involving a prospective study in South Africa. 
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